Hong Pan

State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences & Peking Union Medical College
Tianjin, 300020, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome.

Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome.

Journal: Annals of hematology

Published: February 14, 2026

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

Journal: The New England journal of medicine

Published: January 14, 2026

Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

Journal: Leukemia

Published: December 01, 2025

Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia.

Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia.

Journal: Frontiers in immunology

Published: November 06, 2025

Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study.

Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study.

Journal: Annals of medicine

Published: August 07, 2025

BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.

BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.

Journal: The New England journal of medicine

Published: June 11, 2025

Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.

Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.

Journal: American journal of hematology

Published: May 24, 2025

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.

Journal: Blood

Published: February 27, 2025

Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia.

Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia.

Journal: Cancer immunology, immunotherapy : CII

Published: October 19, 2024

Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study.

Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study.

Journal: Annals of hematology

Published: September 07, 2024

KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T cell large granular lymphocytic leukemia.

KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T cell large granular lymphocytic leukemia.

Journal: Cell reports. Medicine

Published: May 15, 2024

Application of platelet transcriptomics for assessing treatment effectiveness and predicting long-term platelet counts recovery in aplastic anemia.

Application of platelet transcriptomics for assessing treatment effectiveness and predicting long-term platelet counts recovery in aplastic anemia.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 30, 2024

Showing 1-12 of 24

Last Updated: 09/26/2026